## RECEIVED CENTRAL FAX CENTER

OCT 0 1 2007

PTO/SB/04 (07-06)
Approved for use through 01/31/2007. OMB 0551-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT COMMERCE
required to respond to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons an

104831-0002-103 Attorney Docket Number SUPPLEMENTAL Yan Chang First Named Inventor DECLARATION FOR UTILITY COMPLETE IF KNOWN OR DESIGN Application Number 10/657,383 September 8, 2003 PATENT APPLICATION Filing Date Art Unit 1623 (37 CFR 1.67) Examiner Name L. C. Maier I hereby declare that: ach inventor's residence, mailing address, and citizenship are as stated below next to their name. l believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled: METHOD FOR ENHANCING THE EFFECTIVENESS OF CANCER THERAPIES (Title of the invention) the specification of which is attached hereto OR 09/08/2003 was filed on (MM/DD/YYYY) as United States Application Number or PCT International 09/08/2003, 12/23/2003, Application Number 10/657,383 and was amended on (MM/DD/YYYY) 06/01/2004, 08/15/2006 and 05/22/2007 I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.58, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or of any PCT international application having a filing date before that of the application on which priority is claimed. Prior Foreign Foreign Filling Date (MM/DD/YYYY) Country Priority Certified Copy Attached? Application Number(s) Not Claimed YES NO

Page 1 of 3

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

## RECEIVED CENTRAL FAX CENTER

OCT 0 1 2007

PTC/SB/04 (07-06)
Approved for use through 01/31/2007. OMB 0851-0332
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMS control number.

SUPPLEMENTAL DECLARATION — UTILITY OR DESIGN PATENT APPLICATION									
Direct all correspondence to: X The address associated with Customer Number: 28120									
OR Correspondence address below									
Name FISH & NEAVE IP GROUP, ROPES & GRAY LLP Matthew P. Vincent									
One International Place									
City Boston	Sta		tate	MA ZIP 02		110-2624			
Country US	Telephone	(617) 9	951-700	10	Email				
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wiliful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such wiliful false statements may									
Name of Sole or First inventor:	ze the validity of the application or any patent issued thereon.  Sole or First Inventor: X A petition has been filed for this unsigned inventor								
Given Name	Yan				Family Name or Sumame		Chang		
Inventor's Signature							Date		
Ashland Residence: City		United States of America Country			America	US ÇRizenship			
Meiling 79 Winter Street									
Ashland City	MA State		01721 zip.			United States of America Country			
Name of Second Inventor:	X Ap	etiton has be	en filed for	this uns	igned in	ventor			
Given Name		David			Family I or Sum		Platt		
Inventor's Signature							Date		
Newton Center MA Residence: City State		United States of America Country			America	US Citizenship			
Mailing Address: 12 Appleton Circle									
Newton city	MA State		02459 zip			-	United States of America Country		
X Additional inventors or a legal representative are being named on the1_ supplemental sheet(s) PTO/SB/02A or 02LR attached hereto.									

Page 2 of 3

PTO/SB/04 (07-08)
Approved for use through 01/31/2007. OMB 0851-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid CMB control number.

Pursuant to 37 CFR § 1.47(b), the following representative signs on behalf of the person making the instant application on behalf of and as agent for non-signing inventors Yan Chang and David Platt, who refuse to sign the application oath or declaration:

Joseph Grimm, President Prospect Therapeutics, Inc. 1200 Gill Street, Suite 4700 Woburn, Massachusetts 01801 United States of America

Signature

As proof of the above representative's authorization to sign, a Statement Under 37 CFR § 3.73(b) is being filed herewith.

## RECEIVED CENTRAL FAX CENTER

PTO/SB/90C.T. 0 1 2007

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner. Chang et al. Application No./Patent 10/657,383 No./Control No.; Filed/Issue Date: September 8, 2003 METHOD FOR ENHANCING THE EFFECTIVENESS OF CANCER THERAPIES Marlborough Research and Development, (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.) states that it is: x the assignee of the entire right, title, and interest; or 1. 2 an assignee of less than the entire right, title and interest. (The extent (by percentage) of its ownership interest is in the patent application/patent identified above by virtue of either: An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reef , or a true copy of the original assignment is attached. OR A chain of title from the inventor(s), of the patent application/patent identified above, to the current X assignee as follows: 1. From: Chang et al. To: GlycoGenesys, Inc. The document was recorded in the United States Patent and Trademark Office at 016652 , Frame 0688 , or for which a copy thereof is attached. Mark G. DeGiacomo, Chapter 7 · Marlborough Research and 2. From: Trustee of GlycoGenesys, Inc. To: Development, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 018777 , Frame 0643 , or for which a copy thereof is attached. Marlborough Research and 3. From: Development, Inc. To: Prospect Pharmaceuticals, Inc. The document was recorded in the United States Patent and Trademark Office at 018917 , Frame 0374 , or for which a copy thereof is attached. 4. From: Prospect Pharmaceuticals, Inc. To: Prospect Therapeutics, Inc. The document was recorded in the United States Patent and Trademark Office at 018917 Frame 0395 \_ , or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.081 The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee Signature Printed or Typed Name Telephone Number

***************************************				
I hereby certify that this paper (alor	ng with any paper referred to as being atta-	ched or enclosed) i	s being transmitted by I	facsimile to the Patent and
Trademark Office facsimile on (5)	1) 273-8300, on the date shown below.			
	1/2/0 COCO, OH AID COM SHOW! DOIGW.	$\circ$		
Dated: 3/14/07	Signature: Waras Of	- \ \ I T ()		
Dated: 5 // 9 / ( ) /	Signature: Danie	1- 1/X P. 1-	CIMARY Jane DiDa	ima)

## RECEIVED CENTRAL FAX CENTER

OCT 0 1 2007

FAX TRANSMISSION							
DATE: October 1, 2007							
PTO IDENTIFIER: Application Number 10/657,383  Patent Number							
Inventor: Chang et al.							
MESSAGE TO: US Patent and Trademark Office Attn: Office of Petitions							
FAX NUMBER: (571) 273-8300							
FROM: ROPES & GRAY LLP							
Jesse A. Fecker, Ph.D.							
PHONE: (617) 951-7633							
Attorney Dkt. #: 104831-0002-103							
PAGES (Including Cover Sheet):7							
CONTENTS: Request for Reconsideration of Petition Under 37 CFR 1.47(a), 1.183 and 1.48 (2 pages) Supplemental Declaration (3 pages) Copy of 3.73(b) Statement (1 page) This Facsimile Cover Sheet (1 page)							
If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7633 and send the original transmission to us by return mail at the address below.							
This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.							
ROPES & GRAY LLP  One International Place, Boston, Massachusetts 02110  Telephone: (617) 951-7000 Facsimile: (617) 951-7050							